Using CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Holding and Bridging Therapies Are Essential Parts of CAR T Process

During a live event, Thomas G. Martin, MD, discussed the importance of controlling disease and avoiding barriers to access so patients with multiple myeloma can receive CAR T-cell therapy.

Five-Year CAR T Data Reflect Long-Term PFS in Multiple Myeloma

During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.

CAR T Deepens Myeloma Response Over Time, Could Overcome High Risk

During a live event, Adriana Rossi, MD, discussed how cilta-cel induces responses and overcomes high-risk genetics in relapsed multiple myeloma.

Treating Multiple Myeloma With Earlier CAR T-Cell Therapy

During a live event, Adriana Rossi, MD, discussed easing CAR T-cell therapy access and highlighted cilta-cel's efficacy in earlier-line myeloma.

Real-World Evidence Reveals CAR T Sequencing Approach in Myeloma

During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting in multiple myeloma.

Distinguishing Early and Late-Presenting CAR T Toxicities

During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in multiple myeloma.

Coordination Is Essential During and After Referral for CAR T in Myeloma

During a live event, Konstantinos Sdrimas, MD, and community oncologists discussed patient concerns over CAR T-cell therapy toxicity and how to coordinate with CAR T providers.

Social, Logistical Barriers Limit Use of CAR T-Cell Therapy in Myeloma

During a live event, Konstantinos Sdrimas, MD, asked participants what community oncologists should consider when referring patients for CAR T-cell therapy.

Providing Resources for Relocation Expands CAR T Access in RRMM

Samer A. Al’Hadidi, MD, discusses social determinants and resources that can help patients receive chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma.

Considering 3-Year Follow-Up Data of Cilta-Cel in Multiple Myeloma

Samer A. Al’Hadidi, MD, discusses the follow-up data for ciltacabtagene autoleucel in patients with multiple myeloma.

Functional High-Risk is a Leading Rationale for Early CAR T in Myeloma

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory multiple myeloma.

Functional High Risk and Bridging in Multiple Myeloma Considered With CAR T Cells

Samer A. Al'Hadidi, MD, MS, reviewed the benefits of cilta-cel in the subgroup analysis of CARTITUDE-4 in patients with relapsed/refractory multiple myeloma and functional high risk, bridging to cilta-cel, and time to treatment in the second article of a 2-part series.

Efficacy of Cilta-Cel Is Maintained in Early Relapsed Multiple Myeloma

During a Case-Based Roundtable® event, Samer A. Al'Hadidi, MD, MS, discussed the CARTITUDE-4 trial of cilta-cel in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.

Earlier CAR T-Cell Therapy Benefits Functional High-Risk Group in RRMM

Binod Dhakal, MD, MS, discusses why patients could benefit from earlier use of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma.

Patient Selection Factors for Earlier Use of CAR T-Cell Therapy

Binod Dhakal, MD, MS, discusses selecting patients for chimeric antigen receptor T-cell therapy by considering each patient’s condition and logistics.